CN103242307A - 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途 - Google Patents
一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途 Download PDFInfo
- Publication number
- CN103242307A CN103242307A CN2013101830804A CN201310183080A CN103242307A CN 103242307 A CN103242307 A CN 103242307A CN 2013101830804 A CN2013101830804 A CN 2013101830804A CN 201310183080 A CN201310183080 A CN 201310183080A CN 103242307 A CN103242307 A CN 103242307A
- Authority
- CN
- China
- Prior art keywords
- oxo
- oxazolidine
- thiophene
- pyridine
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310183080.4A CN103242307B (zh) | 2013-05-17 | 2013-05-17 | 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途 |
PCT/CN2014/077666 WO2014183665A1 (zh) | 2013-05-17 | 2014-05-16 | 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310183080.4A CN103242307B (zh) | 2013-05-17 | 2013-05-17 | 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103242307A true CN103242307A (zh) | 2013-08-14 |
CN103242307B CN103242307B (zh) | 2015-08-12 |
Family
ID=48922212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310183080.4A Active CN103242307B (zh) | 2013-05-17 | 2013-05-17 | 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN103242307B (zh) |
WO (1) | WO2014183665A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014183666A1 (zh) * | 2013-05-17 | 2014-11-20 | 天津药物研究院 | 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途 |
CN106478661A (zh) * | 2015-08-25 | 2017-03-08 | 华北制药集团新药研究开发有限责任公司 | 苯并恶唑并恶嗪酮类化合物wa1-089的晶型e及其制备方法 |
CN106562981A (zh) * | 2015-10-13 | 2017-04-19 | 孙双勇 | 一种由知非沙班与人参皂苷Rb3组成的药物组合物及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1434822A (zh) * | 1999-12-24 | 2003-08-06 | 拜尔公司 | 取代的噁唑烷酮和其在血液凝固领域中的应用 |
CN101772496A (zh) * | 2007-06-20 | 2010-07-07 | 拜耳先灵制药股份公司 | 取代的*唑烷酮类和其用途 |
CN102464658A (zh) * | 2010-11-03 | 2012-05-23 | 天津药物研究院 | 噁唑烷酮衍生物及其制备方法和用途 |
CN103232446A (zh) * | 2013-05-17 | 2013-08-07 | 天津药物研究院 | 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007028406A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007028319A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
-
2013
- 2013-05-17 CN CN201310183080.4A patent/CN103242307B/zh active Active
-
2014
- 2014-05-16 WO PCT/CN2014/077666 patent/WO2014183665A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1434822A (zh) * | 1999-12-24 | 2003-08-06 | 拜尔公司 | 取代的噁唑烷酮和其在血液凝固领域中的应用 |
CN101772496A (zh) * | 2007-06-20 | 2010-07-07 | 拜耳先灵制药股份公司 | 取代的*唑烷酮类和其用途 |
CN102464658A (zh) * | 2010-11-03 | 2012-05-23 | 天津药物研究院 | 噁唑烷酮衍生物及其制备方法和用途 |
CN103232446A (zh) * | 2013-05-17 | 2013-08-07 | 天津药物研究院 | 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014183666A1 (zh) * | 2013-05-17 | 2014-11-20 | 天津药物研究院 | 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途 |
CN106478661A (zh) * | 2015-08-25 | 2017-03-08 | 华北制药集团新药研究开发有限责任公司 | 苯并恶唑并恶嗪酮类化合物wa1-089的晶型e及其制备方法 |
CN106562981A (zh) * | 2015-10-13 | 2017-04-19 | 孙双勇 | 一种由知非沙班与人参皂苷Rb3组成的药物组合物及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103242307B (zh) | 2015-08-12 |
WO2014183665A1 (zh) | 2014-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102464658B (zh) | 噁唑烷酮衍生物及其制备方法和用途 | |
CN103242307B (zh) | 一种噁唑烷酮类衍生物晶型ⅰ及其制备方法和用途 | |
ES2600783T3 (es) | Régimen de dosificación de edoxabán | |
JPS63126866A (ja) | ピペリジン化合物、その製造方法及びその使用方法 | |
US8691844B2 (en) | Method for treating thrombosis and inhibiting platelet aggregation with 21-(S)-argatroban | |
CN104072434B (zh) | 间位取代的四氮唑苯乙酮化合物、其制备方法和用途 | |
CN103232446B (zh) | 一种噁唑烷酮衍生物晶型ⅱ及其制备方法和用途 | |
CN115381827B (zh) | 苯骈三氮唑烷基衍生物在制备治疗或预防心血管疾病的药物中的应用 | |
BR112020007183A2 (pt) | tratamento de glomeruloesclerose focal segmentado com antagonistas de ccr2 | |
CN104098520B (zh) | 苯基三唑希夫碱类化合物、其制备方法和用途 | |
Eleftheriadis et al. | Differential diagnosis of hyperkalemia: an update to a complex problem | |
Zhang et al. | The synergistic effects of Astragalus mongholicus and Salvia miltiorrhiza on coronary heart disease identified by network pharmacology and experiment | |
CN103340860A (zh) | 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良有效性的方法 | |
CN104163819A (zh) | 一种噁唑烷酮衍生物的乙酸溶剂化物及其制备方法和用途 | |
CN102406938A (zh) | 一种抗血栓的药物组合物 | |
Atreya et al. | ST segment elevation myocardial infarction as a presenting feature of thrombotic thrombocytopenic purpura | |
RU2716141C2 (ru) | Дейтерированные производные тиенопиперидина, способ их получения и применение | |
CN105748424A (zh) | 一种稳定的硫酸氢氯吡格雷阿司匹林双层片及其制备方法 | |
CN102050819A (zh) | 噁唑烷酮衍生物及其制备方法和用途 | |
TW202227457A (zh) | 作為Cdc7抑制劑的鹽型及其晶型 | |
CN101023942A (zh) | 二氢杨梅素治疗心血管疾病的用途 | |
Nwangwa et al. | Deteriorating hemostatic functions of adult female Wistar rats mediated by activities of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)–piroxicam and Vitamin E | |
CN106831904A (zh) | 一种化合物及其制备方法、制剂与应用 | |
Khafagy et al. | Perioperative effects of anesthesia and surgery on inflammation-coagulation interaction | |
CN105106112A (zh) | 一种降压药乌拉地尔组合物水针剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Applicant after: TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH CO., LTD. Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Applicant before: Tianjin Institute of Pharmaceutical Research |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH TO: TIANJIN PHARMACEUTICAL INSTITUTE CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201012 Address after: 300171 No. eight, No. 109, Hedong Road, Hedong District, Tianjin Patentee after: Tianjin Drug Group Ltd. Address before: 300193 Tianjin City, Nankai District Anshan West Road No. 308 Patentee before: Tianjin Institute of Pharmaceutical Research Co.,Ltd. |